FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280632285> ?p ?o ?g. }

• W4280632285 endingPage "55" @default.
• W4280632285 startingPage "48" @default.
• W4280632285 abstract "When choosing the frst drug for genetically engineered biological therapy (GEBT), the following are taken into account: the psoriasis phenotype, diagnosed PsA or predictors of its development, the presence of comorbid pathology, contraindications, dosing regimen, the rate of onset of the effect, and the ‘survival rate’. With the advent of new classes of GEBT-drugs, the concept of ‘treat to target’ has been formed, in accordance with which the importance of achieving clear or almost clear skin as a goal of psoriasis therapy has been noted, since studies have shown that achieving clear or almost clear skin (PASI 90, 100) correlates with higher indicators of health-related quality of life. The concept is reduced to the long-term prescription of highly effective and safe therapies (methods) with a high level of evidence in medicine (A, B). The evolution of GIBT has led to the emergence of a new class of anti-IL-23 drugs. The article presents data from clinical studies on the effcacy and safety of the use of the interleukin-23 blocker guselcumab. Own clinical cases are presented with a discussion of the choice made in favor of guselcumab as the frst genetically engineered drug. Conclusions. Data from clinical trials on the high effcacy, ‘survival rate’ and safety of guselcumab in patients with psoriasis and psoriatic arthritis allows, including those with comorbid pathology, to consider it as a starting therapy using genetically engineered drugs. The data of our own results of observation allow us to conclude that guselkumab is highly effective in psoriasis of smooth skin, as well as in lesions of the scalp, anogenital area, with involvement of the nail plates in the process, which justifes its appointment as the frst GIBT drug." @default.
• W4280632285 created "2022-05-22" @default.
• W4280632285 creator A5058108562 @default.
• W4280632285 creator A5087370326 @default.
• W4280632285 creator A5087841320 @default.
• W4280632285 creator A5091517102 @default.
• W4280632285 date "2022-05-18" @default.
• W4280632285 modified "2023-09-27" @default.
• W4280632285 title "Choice of frst drug of genetically engineered therapy: Benefts of guselcumab" @default.
• W4280632285 cites W1515251814 @default.
• W4280632285 cites W1990504563 @default.
• W4280632285 cites W2011059902 @default.
• W4280632285 cites W2017932566 @default.
• W4280632285 cites W2034350610 @default.
• W4280632285 cites W2105477284 @default.
• W4280632285 cites W2110427394 @default.
• W4280632285 cites W2121126920 @default.
• W4280632285 cites W2156866935 @default.
• W4280632285 cites W2570140560 @default.
• W4280632285 cites W2570141807 @default.
• W4280632285 cites W2613397542 @default.
• W4280632285 cites W2697574135 @default.
• W4280632285 cites W2783629352 @default.
• W4280632285 cites W2894504400 @default.
• W4280632285 cites W2908033840 @default.
• W4280632285 cites W2910751255 @default.
• W4280632285 cites W2932943837 @default.
• W4280632285 cites W2936274452 @default.
• W4280632285 cites W2952406328 @default.
• W4280632285 cites W2967449819 @default.
• W4280632285 cites W2985925251 @default.
• W4280632285 cites W3005392748 @default.
• W4280632285 cites W3015886911 @default.
• W4280632285 cites W3042327007 @default.
• W4280632285 cites W3042689359 @default.
• W4280632285 cites W3097649889 @default.
• W4280632285 cites W3104355512 @default.
• W4280632285 cites W4211261385 @default.
• W4280632285 cites W4234268300 @default.
• W4280632285 cites W4248095883 @default.
• W4280632285 doi "https://doi.org/10.33667/2078-5631-2022-8-48-55" @default.
• W4280632285 hasPublicationYear "2022" @default.
• W4280632285 type Work @default.
• W4280632285 citedByCount "0" @default.
• W4280632285 crossrefType "journal-article" @default.
• W4280632285 hasAuthorship W4280632285A5058108562 @default.
• W4280632285 hasAuthorship W4280632285A5087370326 @default.
• W4280632285 hasAuthorship W4280632285A5087841320 @default.
• W4280632285 hasAuthorship W4280632285A5091517102 @default.
• W4280632285 hasConcept C104317684 @default.
• W4280632285 hasConcept C126322002 @default.
• W4280632285 hasConcept C16005928 @default.
• W4280632285 hasConcept C177713679 @default.
• W4280632285 hasConcept C2426938 @default.
• W4280632285 hasConcept C2776260265 @default.
• W4280632285 hasConcept C2777288759 @default.
• W4280632285 hasConcept C2780035454 @default.
• W4280632285 hasConcept C2780564577 @default.
• W4280632285 hasConcept C3019111730 @default.
• W4280632285 hasConcept C535046627 @default.
• W4280632285 hasConcept C55493867 @default.
• W4280632285 hasConcept C71924100 @default.
• W4280632285 hasConcept C86803240 @default.
• W4280632285 hasConcept C98274493 @default.
• W4280632285 hasConceptScore W4280632285C104317684 @default.
• W4280632285 hasConceptScore W4280632285C126322002 @default.
• W4280632285 hasConceptScore W4280632285C16005928 @default.
• W4280632285 hasConceptScore W4280632285C177713679 @default.
• W4280632285 hasConceptScore W4280632285C2426938 @default.
• W4280632285 hasConceptScore W4280632285C2776260265 @default.
• W4280632285 hasConceptScore W4280632285C2777288759 @default.
• W4280632285 hasConceptScore W4280632285C2780035454 @default.
• W4280632285 hasConceptScore W4280632285C2780564577 @default.
• W4280632285 hasConceptScore W4280632285C3019111730 @default.
• W4280632285 hasConceptScore W4280632285C535046627 @default.
• W4280632285 hasConceptScore W4280632285C55493867 @default.
• W4280632285 hasConceptScore W4280632285C71924100 @default.
• W4280632285 hasConceptScore W4280632285C86803240 @default.
• W4280632285 hasConceptScore W4280632285C98274493 @default.
• W4280632285 hasIssue "8" @default.
• W4280632285 hasLocation W42806322851 @default.
• W4280632285 hasOpenAccess W4280632285 @default.
• W4280632285 hasPrimaryLocation W42806322851 @default.
• W4280632285 hasRelatedWork W2261311603 @default.
• W4280632285 hasRelatedWork W2417900408 @default.
• W4280632285 hasRelatedWork W2463001945 @default.
• W4280632285 hasRelatedWork W2467573732 @default.
• W4280632285 hasRelatedWork W2601256796 @default.
• W4280632285 hasRelatedWork W2948178223 @default.
• W4280632285 hasRelatedWork W2985439789 @default.
• W4280632285 hasRelatedWork W3195838575 @default.
• W4280632285 hasRelatedWork W4256724032 @default.
• W4280632285 hasRelatedWork W92320395 @default.
• W4280632285 isParatext "false" @default.
• W4280632285 isRetracted "false" @default.
• W4280632285 workType "article" @default.